Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors

Bevacizumab was shown to be effective in the treatment of brain radiation necrosis (RN) attributed to the use of stereotactic radiosurgery (SRS). Data on its efficacy and safety in non-small cell lung cancer (NSCLC) patients treated with immune check-point inhibitors (ICI) is lacking.

Source: Journal of the Neurological Sciences - June 24, 2021 Category: Neurology Authors: Assaf Moore, Shlomit Yust-Katz, Oded Icht, Ruth Eliyahu, Noa Gordon, Aharon Yehonatan Cohen, Iris Magdalena Goldstein, Nir Peled, Tali Seigal, Alexandra Amiel, Elizabeth Dudnik Source Type: research